International Journal of Endocrinology

Volume 2013 (2013), Article ID 569831, 12 pages

http://dx.doi.org/10.1155/2013/569831

Review Article

Inflammatory Factors and Exercise in Chronic Kidney Disease

Maurice Dungey,1,2 Katherine L. Hull,2,3 Alice C. Smith,2,3 James O. Burton,2,3 and Nicolette C. Bishop1,2

¹School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire LE11 3TU, UK

²Leicester Kidney Exercise Team, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK

³Department of Infection, Immunity and Inflammation, Maurice Shock Medical Sciences Building, University Road, Leicester LE1 9HN, UK

Received 28 December 2012; Revised 19 April 2013; Accepted 19 April 2013

Academic Editor: Stephen L. Atkin

Copyright © 2013 Maurice Dungey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Patients with chronic kidney disease frequently present with chronic elevations in markers of inflammation, a condition that appears to be exacerbated by disease progression and onset of haemodialysis. Systemic inflammation is interlinked with malnutrition and muscle protein wasting and is implicated in a number of morbidities including cardiovascular disease: the most common cause of mortality in this population. Research in the general population and other chronic disease cohorts suggests that an increase in habitual activity levels over a prolonged period may help redress basal increases in systemic inflammation. Furthermore, those populations with the highest baseline levels of systemic inflammation appear to have the greatest improvements from training. On the whole, the activity levels of the chronic kidney disease population reflect a sedentary lifestyle, indicating the potential for increasing physical activity and observing health benefits. This review explores the current literature investigating exercise and inflammatory factors in the chronic kidney disease population and then attempts to explain the contradictory findings and suggests where future research is required.

1. Chronic Kidney Disease

Chronic kidney disease (CKD) refers to the progressive and irreversible decline in renal function and is defined as kidney damage for ≥3 months based on findings of abnormal structure or function or glomerular filtration rate (GFR) <60 mL/min/1.73 m² for ≥3 months with or without evidence of kidney damage [1]. There are five different stages of CKD, determined by measuring a patient’s estimated GFR (eGFR). Severity of disease is classified using stages of increasing severity from 1 to 5 (Table 1).

Table 1: Progression of chronic kidney disease [2].

CKD stage
Description
GFR (mL/min/1.73 m²)

1
Renal damage with increased or normal GFR
≥90

2
Renal damage with a mild reduction in GFR
60–89

3a
Moderate reduction in GFR with or without evidence of other renal damage
45–59

3b
30–44

4
Severe reduction in GFR with or without evidence of renal damage
15–29

5
Established renal failure
<15

CKD: chronic kidney disease; GFR: glomerular filtration rate.

Use the suffix (p) to denote the presence of proteinuria when staging CKD and define proteinuria as urinary ACR (albumin : creatinine ratio) ≥30 mg/mmol, or PCR (protein : creatinine ratio) ≥50 mg/mmol.

Patients with CKD stages 1-2 have relatively normal eGFR and few symptoms. In secondary care, most CKD patients will either be predialysis (CKD stages 3–5) or end-stage renal disease (ESRD) patients. Management of predialysis patients aims to reduce the rate of decline in renal function and the likelihood of reaching ESRD, avoid and treat complications and comorbidities of CKD, and provide symptomatic relief.

Patients with ESRD require renal replacement therapy (RRT), a treatment which is advised to start once eGFR <15 mL/min and the patient is symptomatic [1]. RRT options include transplantation or dialysis: haemodialysis (HD), haemofiltration, and peritoneal dialysis (PD). Transplantation and HD are the most common types of treatment modalities, accounting for 48% and 44% of RRT techniques respectively [3].

The numerous aetiologies of CKD can be grouped as genetic, glomerular, vascular, and tubulointerstitial diseases or due to urinary tract obstruction [4]. The most common causes are related to diabetes and hypertension [1]. Despite the vast number of causes, classification of renal function into the five stages and long-term management are usually similar [4]. Progressive renal dysfunction is associated with numerous complications as a result of the kidney’s regulatory, endocrine, excretory, and metabolic functions. Such complications include anaemia, renal osteodystrophy, pruritus, nephrogenic systemic fibrosis, metabolic abnormalities (e.g., gout, insulin resistance, and dyslipidaemia), endocrine abnormalities (e.g., impaired growth in children due to perturbations in growth hormone action and erectile dysfunction due to decreased testosterone levels), muscle dysfunction, nervous system dysfunction, calciphylaxis, and cardiovascular disease [4]. These complications and the subsequent symptoms may vary between individuals, the origin of the CKD, and comorbidities. However, the majority of complications are exacerbated by declining renal function and progression to ESRD.

CKD is a worldwide health problem which increases in prevalence with age; a global systematic review reported a median prevalence of CKD stage 3 and greater of 7.2% in individuals aged over 30 years of age, and between 23.4% and 35.8% in those aged 64 years or older [5]. The risk of mortality is substantially elevated in this population [6]; the average 5-year survival of western dialysis patients aged 60 years is approximately 45% (data from UK, Swedish, and USA registries).

Not all CKD patients progress to ESRD; rather, in all stages of CKD, death is a far more common event than the initiation of RRT. Keith et al. followed 28,000 patients with CKD stages 2, 3, and 4 with 1.1%, 1.3%, and 19.9% reaching ESRD and mortality rates of 19.5%, 24.3%, and 45.7% respectively [7]. Furthermore, in a retrospective cohort study observing 1076 patients over a five- and a half-year period found that 4% developed ESRD and 69% had died, with 46% of deaths cardiovascular in origin [8]. Cardiovascular disease (CVD) is the most frequent cause of mortality, with CKD itself being an established risk factor for CVD [9]. Deteriorating kidney function is associated with an increased risk of CVD at every stage of CKD [10].

As the major cause of comorbidity and mortality in the CKD population, cardiovascular risk is an important target for intervention. The development of coronary atherosclerosis and endothelial dysfunction is a multifaceted inflammatory process [4]. In CVD, the presence of inflammation has been implicated at inception and every stage of the atherosclerotic process thereafter: from adhesion molecule expression on endothelial cells, penetration of monocytes into the intima, creation of fatty streaks, enhanced inflammatory response, development of the complex plaque, weakening of the fibrous collagen cap, and increased risk of thrombosis [11]. Chronic inflammation is also associated with other complications and comorbidities frequently seen in CKD such as conditions affecting the endocrine system (insulin resistance and metabolic syndrome) and neurological system (depression) [12]. CKD itself presents a complex multidimensional inflammatory condition.

2. Inflammation and Chronic Kidney Disease

Inflammation is a rapid and acute protective response to infection or trauma. The activation of the complement pathway stimulates the degranulation of mast cells and the release of inflammatory cytokines [4]. This has both local (redness, swelling, heat production, and pain) and systemic consequences (fever) due to changes in local blood flow and the effect of cytokines on the hypothalamus, respectively. Systemic inflammatory cytokines (Interleukin-1 (IL-1), IL-6, and tumour necrosis factor-alpha (TNF-α)) stimulate hepatocytes to secrete the acute-phase protein C-reactive protein (CRP), the most widely used marker of inflammation. The initial reaction to damaging stimuli is a normal and necessary process to help contain infection and begin the cascade of events involved in the immune response. However, when the initial insult cannot be acutely resolved or when anti-inflammatory systems responsible for regulating inflammation are dysfunctional, inflammation persists. A chronic inflammatory state is harmful, rather than protective, as it may result in end organ and vascular damage [4].

In CKD, chronic inflammation plays an important role in the disease process and high levels of CRP appear to accompany reduced renal function [13]. Within the predialysis CKD population the prevalence of inflammation is great and is an important indicator of patient health and outcome; high levels of CRP reflect a chronic inflammatory state associated with reduced serum albumin levels, inadequate response to erythropoietin replacement, and greater hospitalisation [14]. However, the actual effect of chronic inflammation on renal function is unclear as although inflammation is prevalent within the predialysis CKD population, the relationship between the level of inflammation (using CRP or inflammatory cytokines such as IL-6 as surrogate markers), and eGFR has not been found to correlate [14, 15], as may be expected. In addition, in many of the aetiologies of CKD, inflammation has a role in their pathogenesis. Thus, it is unclear whether it is renal insufficiency or the disease origin causing chronic inflammation in the first stages of CKD.

In ESRD, the process of HD itself may contribute to the pro-inflammatory state. For instance, exposure to the dialysis membrane may stimulate an acute-phase response and an increase in inflammatory cytokine levels [16]. Furthermore, it appears that this exposure and the type of dialysis membrane itself are greater determinant in stimulating the acute-phase response than the bacterial nature of the dialysate [17]. However, HD is not the only source of inflammation since predialysis CKD patients have elevated levels of inflammatory markers, as previously discussed, and some research has found a number of HD patients that have normal CRP levels [18]. Thus, it may be proposed that other mechanisms are involved in the inflammatory state, including processes contributing to uraemia [19]. A number of factors with the potential to induce inflammation in CKD have been described (Table 2).

Table 2: Summary of the potential causes of chronic inflammation in chronic kidney disease (adapted from Cheung et al. [26]).

Causes of inflammation in CKD
Additional inflammatory factors relating to dialysis

(i) Decreased GFR

(ii) Decreased clearance or increased production of pro-inflammatory cytokines

(iii) Volume overload

(iv) Oxidative stress

(v) Carbonyl stress

(vi) Deteriorating nutritional state and food intake

(vii) Alterations in body composition

(viii) Uraemic toxins

(ix) Infection

(x) Genetic and epigenetic factors
(i) Intravenous catheter, peritoneal dialysis catheter and its related infections

(ii) Dialysis membranes with poor biocompatibility

(iii) Impurities in dialysis water and dialysate

(iv) Back-filtration or back-diffusion of contaminants

(v) Constant exposure to peritoneal dialysis solution

(vi) Peritonitis

CKD: chronic kidney disease; GFR: glomerular filtration rate.

While the source(s) of chronic inflammation in CKD can vary, the negative implications of elevated inflammatory markers are clear. For example, an increase or persistent elevation in markers of inflammation (CRP, IL-6, and TNF-α) are highly predictive of mortality [20].

The relatively long 19-hour half-life of CRP makes it easy to detect; thus, CRP is frequently used as a clinical marker of inflammation. However, IL-6 has been reported as a better prognostic marker than both CRP and TNF-α [21] in haemodialysis and predialysis CKD populations [22]. Moreover, IL-6 is a particularly interesting molecule due to its divergent roles as both a pro- and anti-inflammatory factor.

The role of IL-6 appears to be context and source dependent. At rest, circulating concentrations of IL-6 are attributed to adipocytes and macrophages resident within adipose tissue [23], uraemia-induced immune dysfunction [24], and other causes (Table 2). An acute infusion of IL-6 leads to transient increases in a number of anti-inflammatory factors (cortisol, IL-10, IL-1 receptor antagonist (IL-1ra)) without a change in TNF-α [25]; the anti-inflammatory effect of myocyte secretion of IL-6 is discussed later. Thus, it appears that transient increases in IL-6 which are well-regulated by an effective anti-inflammatory response are not detrimental; it is when IL-6 is chronically elevated and represents an inflammatory milieu (e.g., immune dysfunction) that IL-6 concentrations are associated with poor outcome.

Pro-inflammatory cytokines are pleiotropic in their nature and impact upon numerous conditions that frequently accompany CKD. Systemic inflammation has a role in malnutrition and protein-energy wasting, atherosclerosis, endocrine disorders, and depression [27]. With regards to malnutrition and protein-energy wasting in CKD, these comorbidities are interlinked and share common aetiologies, yet the contribution of each aspect to poor outcome is not well defined. Therefore, “malnutrition-inflammation-cachexia syndrome” (MICS) has been suggested to denote the important contribution of these conditions to outcome in CKD [28]. The adverse effects of MICS develop at a greater rate in ESRD than the traditional risk factors for CVD, such as obesity and hypercholesterolaemia [29], and are important predictors of prognosis [30].

IL-6 has been implicated in the breakdown of muscle protein in other cachexic populations [31] and related to markers of wasting in CKD patients [32]. IL-6 inhibits insulin-like growth factor-1 (IGF-1) secretion and consequently growth and repair [33]. Insulin resistance, reduced appetite, increased basal energy expenditure, and activation of the ATP-ubiquitin proteolytic pathway have been suggested as conditions by which chronic inflammation instigates muscle wasting [27].

Chronic elevations in leptin may also contribute to muscle protein wasting [34]. A leptin receptor-deficient mice model exhibited elevated leptin levels after undergoing nephrectomy but resisted cachexic effects [35].

It is noteworthy that a number of anti-inflammatory cytokines are also elevated in CKD. For instance, IL-10 increases in response to inflammation and in healthy individuals it is predominantly cleared by the kidneys. Consequently IL-10 is frequently found to be higher in CKD than healthy populations [36]. In addition to its anti-inflammatory benefits, IL-10 may have anti-atherosclerotic effects [36]. In the majority of CKD patients the elevations in pro-inflammatory factors outweigh any anti-inflammatory increases; however, the subjects with the highest IL-10 levels have a better immune balance, as shown by improved response to vaccination [37].

Overall, CKD patients exhibit elevations in markers of chronic inflammation [26]. Since inflammation, malnutrition and protein-energy wasting are significant contributors to mortality in CKD patients [38], any treatments which may positively influence these conditions should be explored. The concept of exercise as medicine is an area of increasing interest due to its wide range of diverse beneficial effects [39].

3. Physical Activity and Inflammation in the General Population

There is now a growing body of evidence to support the notion that circulating markers of systemic inflammation are lower in individuals who regularly engage in physical activity. Indeed, a systematic review of literature on this topic published between 1975 and 2004 concluded that regular physical activity is associated with a long-term “anti-inflammatory effect” [40]. For example, cross-sectional observational studies in apparently healthy people consistently report inverse relationships between circulating markers of systemic inflammation and physical activity levels or fitness [41–44]. Key criticisms of this literature have been the tendency to focus on cohorts of a narrow age range (often middle-aged or older), not taking into account confounders such as BMI and leisure time activity as opposed to overt exercise activities. A recent study to address these points assessed CRP and several cytokines including IL-6, IL-10, TNF-α, and monocyte chemoattractant protein-1 (MCP-1) in almost 1000 men and women (40% men, 60% women) ranging in age from 18 to 85 years and BMI of 16.7–52.7 kg/m² [45]. Plasma levels of CRP, IL-6, and TNF-α were significantly lower when comparing high-to-low tertiles for leisure time exercise frequency and perceived levels of fitness, even after adjustment for BMI, age, sex, and smoking. Interestingly, despite this effect BMI was still ranked as the most important influencing factor for CRP and IL-6 levels, with age the most important for TNF-α levels. There was no effect of either perceived fitness or leisure time exercise frequency on IL-10 and MCP-1.

The findings of a recent 10-year follow-up study also lend strong support to the role of regular exercise in lowering plasma levels of IL-6 and CRP [46]. Findings from a cohort of over 4000 male and female UK Government workers found that those meeting the physical activity recommendations for cardiovascular health (2.5 h/wk of moderate to vigorous physical activity) had lower CRP and IL-6 levels at baseline and at 10-year follow-up, even after adjusting for age, sex, smoking, BMI, employment grade and chronic illness. An increase in physical activity was also associated with lower levels of IL-6 and CRP at follow-up. Importantly, these observed associations were independent of central adiposity as the effects persisted when data were adjusted for waist circumference.

The findings of Hamer et al. [46] appear to suggest that regular activity needs to be performed for a period of years before the benefits of exercise independent of weight loss and reduced adiposity are observed. Certainly the majority of intervention studies that have implemented aerobic training programmes lasting 12 months or less generally report either no effect or a lowering of inflammatory markers only when in combination with weight loss [47–50]. However, differences in exercise prescription, baseline levels of inflammatory markers, and time after intervention of the final blood sample may also influence study findings: Thompson et al. reported significant, albeit modest (0.4 pg/mL) falls in plasma IL-6 in previously sedentary men after just 12 weeks of a 24-week progressive training programme (progressing from 30-minute sessions at 50% of maximal aerobic capacity to 1-hour sessions at 70% of maximal aerobic capacity), compared with non-exercising controls [50]. This was associated with significant, yet modest falls in body mass (~1.6 kg) and BMI (~0.7 kg/m²) after 24 weeks. However, the effect on IL-6 (but not body mass or BMI) was reversed within 2 weeks of the last training session; this could have important implications because it is not uncommon for studies to collect post-intervention blood samples 7–14 days after the last training session.

Examination of the literature suggests that investigation of the mechanisms by which exercise exerts its anti-inflammatory effects has been largely focused on the effects of reduced adiposity and expression and release of adipose tissue-derived inflammatory cytokines [51]. Adipose tissue is recognised as a metabolically active tissue that plays a key role in the development of chronic low-grade inflammation. Adipose tissue is able to produce inflammatory cytokines such as TNF-α, IL-1β, IL-6, and several potent chemoattractant cytokines (chemokines) including MCP-1, macrophage inflammatory protein-1a (MIP-1a) and the T (and monocyte) chemokine regulated on activation, normal T cell secreted, and expressed (RANTES) [52, 53]. The accumulation of monocytes as macrophages in adipose tissue is thought to be a major source of increased systemic concentrations of inflammatory cytokines [54]. With this in mind, increased physical activity and dietary restriction that results in a negative energy balance and consequently reduces adiposity, have been typically suggested as the main mechanism by which exercise exerts its beneficial effects on the level of circulating inflammatory markers. However, non-obese healthy individuals who take part in regular physical activity also have reduced circulating levels of systemic inflammation, particularly IL-6 and CRP, compared with non-obese healthy individuals who adopt a sedentary lifestyle [41, 42, 55]. Furthermore, the ten-year observational study by Hamer et al. reported lower levels of IL-6 and CRP in those meeting the UK Physical Activity Guidelines for health compared with those that did not, and this effect persisted even after adjusting for body mass index and waist circumference [46]. Therefore the positive impacts of increasing activity levels are not restricted to those achieved through reducing adiposity.

Several other potential mechanisms have now been suggested to contribute to the lowering of circulating markers of systemic inflammation in those who are physically active [51]. One possible mechanism that has been the focus of much recent attention is the increased production and release of cytokines from contracting skeletal muscle “myokines” during exercise [56]. Muscle and circulating levels of IL-6 increase in response to exercise loads of sufficient duration and to a lesser extent, intensity. Although increases in circulating IL-6 levels of over 100-fold have been detected after prolonged exercise lasting over 2.5 hours [57], more modest increases are detectable after shorter-duration exercise [58] and also in response to resistance exercise [59, 60]. A major stimulus for IL-6 release is a fall in muscle glycogen content [61, 62] but increases in intracellular calcium levels, and formation of reactive oxygen species also plays a role in activating transcription factors known to regulate synthesis of IL-6 [58]. Increases in circulating levels of IL-6 appear to stimulate the release of anti-inflammatory cytokines IL-10 and IL-1ra and inhibits the release of the pro-inflammatory cytokines IL-1β and TNF-α [56], creating a circulating “anti-inflammatory” environment with every bout of exercise. It should also be noted that the half-life of IL-6 is prolonged by combining with the soluble IL-6 receptor (sIL-6R), muscle membrane expression of sIL-6R is also increased by exercise training [61].

Muscle release of IL-6 and the subsequent cascade of anti-inflammatory cytokines cannot be the sole mechanism underlying the so-called anti-inflammatory effects of exercise because short durations of low-to-moderate intensity of exercise are associated with reductions in circulating concentrations of markers of inflammation and yet do not stimulate IL-6 release [58]. A recent review of further mechanisms thought to be involved in the beneficial effects of exercise on inflammation [51] highlighted reduced expression of toll-like receptors on monocytes and macrophage with subsequent inhibitory effects on monocyte/macrophage IL-6 and TNF-α production, inhibition of monocyte/macrophage infiltration into adipose tissue, phenotypic switching of macrophages from a pro-inflammatory phenotype to an anti-inflammatory phenotype within adipose tissue, a reduction in the circulating numbers of pro-inflammatory monocytes, and an increase in the circulating numbers of regulatory T cells as having a potential role. In particular, toll-like receptors (TLRs) may play a key role in the link between a sedentary lifestyle, inflammation, and disease because both exercise training studies and cross-sectional comparisons between physically active, and sedentary individuals have shown reduced monocyte TLR4 expression and stimulated IL-6 release with increased amounts of activity [63, 64].

4. Physical Activity and Chronic Kidney Disease

Physical inactivity is associated with an increased risk of development of CKD [65, 66]. Inactive ESRD patients are at an increased risk of mortality (hazard ratio: 1.62) [67] and patients that report exercising 2-3 or 4-5 times a week have a reduced relative risk of mortality (0.74 and 0.70 resp.) in comparison to sedentary counterparts [68].

As a whole CKD patients are a sedentary population, activity levels are significantly lower than those recommended by national guidelines [69]. Peak aerobic capacity is markedly lower in CKD stages 3–5 than healthy reference groups [70]. Consequently, results from physical function tests (sit-to-stand test, hand-grip, up-and-go test, and 6-minute walk test) are frequently lower than would be expected [71–73].

Maximal exercise tolerance is affected in the very early stages of CKD [70]. Exercise capacity and physical activity levels correlate with eGFR [74, 75] therefore suggesting that physical fitness and activity levels decline as the disease severity worsens. ESRD patients have significantly lower daily activity-related energy expenditure than healthy sedentary controls, and this disparity is exacerbated on days when patients receive haemodialysis treatment [69, 76]. Self-reported physical activity levels are a good predictor of post-dialysis fatigue scores; patients who are most active report reduced fatigue levels [77]. Consequently, decreased physical activity levels and fitness represent the beginning of a vicious cycle of declining fitness, activity, physical function, and disability which if left unchecked will continue to escalate. A shift in sedentary behaviour to a more active lifestyle should have survival benefits in individuals with CKD.

5. Exercise and Inflammatory Factors in Chronic Kidney Disease

5.1. Observational Studies

Despite smaller cohorts and a limited depth of literature, associations between inflammatory markers and physical fitness or activity levels in CKD patients correspond with findings from healthy populations. In a study of over 200 dialysis patients self-reported physical activity levels correlated inversely with CRP [78]. These findings were supported in ESRD patients who wore SenseWear physical activity monitors for 7 days; circulating CRP >5 mg/L was associated with lower energy expenditure and steps walked than patients with lower concentrations of CRP [79]. In contrast Zamojska and colleagues found no such relationships between CRP and steps walked [80]; this may be explained by the short duration of activity monitoring (2 days) and the exclusion of all patients who reported difficulty walking or physical impairments.

In a mixed predialysis and ESRD patient cohort the main determinant of CRP was VO2peak; the higher the aerobic capacity of the patient, the lower their inflammatory state () [81]. Large cohort studies measuring numerous inflammatory factors are required to further establish the relationship between greater fitness and activity levels and an improved lower systemic inflammatory state.

Observational studies do not give an insight into the mechanisms behind relationships, nor do they help provide evidence of causation. Although there is an association between activity levels and inflammatory factors, it is unclear as to whether this is due to a protective role of regular physical activity. This observed association may be attributed to the role of inflammatory cytokines in muscle catabolism [27], and subsequent reduction in physical capacity and physical activity levels. However, since numerous training studies have been shown to yield favourable adaptations to aerobic and functional capacity [82], a two-way negative relationship between physical activity and inflammation is likely.

5.2. Longitudinal Studies

A growing number of exercise interventions have been trialled in CKD patients, a recent review and meta-analysis concluded that regular exercise in the CKD population provides significant improvements in physical fitness, cardiovascular dimensions, nutritional parameters, and health-related quality of life [83]. Studies reporting inflammatory factors as outcome measures are scarce.

5.2.1. ESRD Patients

A few early exercise intervention studies investigating inflammatory factors within ESRD patients have been published in the last decade; to date results have been inconclusive (Table 3). A few studies have reported no changes in inflammatory cytokines that is, IL-6 [84, 85]and the acute phase protein CRP [86–89], and others have reported decreased levels of circulating CRP after training [90–94].

Table 3: Exercise intervention studies in haemodialysis patients.

Study
Design

(Number of patients)
Training
Outcome measures:

Exercise versus control (unless stated otherwise)

Afshar et al., 2010 [93]
RCT

(7 aerobic, 7 resistance, 7 CON)
Aerobic: ID cycling: RPE 12–14

10–30 min, 3x/wk, 8 wks

Resistance exercises: RPE 15–17; 3x/wk, 8 wks
Aerobic versus resistance versus CON

Hs-CRP: −83.9% versus −67.9% versus +1.5%

Serum creatinine: −65.6% versus −59.9% versus +1.2%

Albumin: NC

Afshar et al., 2011 [94]
RCT

(14 EX versus 14 CON)
ID cycling @ RPE 12–14

10–30 min 3x/wk, 8 wks
Serum leptin: −19.9% versus +29.2%

CRP: −83.2% versus +1.2%

Cheema et al., 2007 [92]

Cheema et al., 2011 [85]
RCT

(24 EX versus 25 CON)
ID PRT: 2 sets 10 exercises @ RPE 15–17 using free weights.

3x/wk, 12 wks
Total strength: +15.2 versus −2.4 kg

Mid-thigh circumference: +0.7 versus −0.3 cm

Log CRP: −0.08 versus +0.24

TNF-α: NC

IL-1β: NC

IL-6: NC

IL-10: NC

IL-12: NC

Daniilidis et al., 2004 [84]
RCT

(20 EX versus 14 CON)
NDT aerobic interval exercises (steps, treadmill, gymnastics, swimming, and ball games) @ 75–85% HRpeak 

60 min, 3x/wk, 6 months
VO2peak: +42% versus NC

IL-2: NC

IL-4: NC

IL-6: NC

T-lymphocyte subsets: NC

Golebiowski et al., 2012 [89]
Uncontrolled

(29 EX)
ID cycling

3x/wk 3 months
6 min walk velocity: +4%

CRP: NC

IL-6: NC

Kopple et al., 2007 [86]
RCT

(10 end-EX, 15 Str-EX, 12 Com-EX, 14 CON, 20 healthy-CON)
End-EX: ID cycling up to 40 min @ approx. 50% VO2peak 

Str-EX: NDT leg resistance exercise

3 sets of 6–8 reps @ 80% of 5 RM

Com-EX: half End-EX/half Str-EX

All: 3x/wk, 18 wks
Duration and work rate of exercise sessions: significant improvement in all exercise groups.

CRP: NC

TNF-α: NC

IL-6: NC

Nindl et al., 2004 [91]

(Headley et al., 2002 [95])
Uncontrolled

(10 EX)
NDT: PRT using 9 resistance machine exercises

1–3 sets 15x reps

2x/wk, 12 wks

6 min walk test distance: +5%

Peak torque: +12.6%

CRP:

    week −6: 12.42 ± 2.96 mg/L;

    week 0: 10.37 ± 2.71 mg/L;

    week 6: 7.55 ± 1.57 mg/L;

    week 12: 6.12 ± 1.07 mg/L

Toussaint et al., 2008 [87]
Randomised crossover

()
ID cycling 30 min 3x/wk

3 months (1 month washout)
3 months EX versus 3 months non-EX

CRP: NC

Wilund et al., 2010 [88]
RCT

(8 EX versus 9 CON)
ID cycling, 45 min @ RPE 12–14

3x/wk, 4 months
Shuttle walk test distance: +17% versus NC

CRP: NC

IL-6: NC

Zatuska et al., 2002 [90]
Uncontrolled

(10 EX)
ID cycling

30 min, 3x/wk, 6 months
CRP: decrease ()

CON: control; CRP: C-reactive protein; EX: exercise; HRpeak: peak heart-rate; Hs: high-sensitivity; ID: intradialytic; IL: interleukin; NC: no significant changes; NDT: non-dialysis time; PRT: progressive resistance training; RCT: randomised controlled trial; RM: repetition maximum; RPE: rating of perceived exertion; TNF-α: tumour necrosis factor-alpha.

As an illustration of the contradictory findings: Cheema and colleagues reported an improvement in inflammatory status due to a reduction in CRP concentrations after 12 weeks of progressive resistance training [92]. However, upon later analysis no changes in pro- or anti-inflammatory cytokines were reported in the same cohort (IL-1β, TNF-α, IL-6, IL-8, IL-10, and IL-12) although greatest muscular hypertrophic adaptations were associated with the greatest reductions in resting IL-6 levels [85].

Notably, two studies from a single research group gave surprisingly large positive changes after a modest training programme. In two randomised controlled trails, 8 weeks of cycling for 10–30 minutes at intensity perceived to be “somewhat hard” produced over 80% reductions in circulating CRP and a 20% decline in serum leptin concentrations [93, 94]. Since other studies have not found such dramatic results in longer studies of patients training at a greater intensity, it appears advisable to interpret these results with caution.

5.2.2. Predialysis Patients

There is an even greater paucity of research in predialysis patients (Table 4). Exercise research is in its infancy in this disease population, only a few relevant studies have been completed which report conflicting results. A 12-week supervised progressive resistance training programme produced type I and type II muscle fibre hypertrophy, improvements in muscular strength, and concomitant reductions in IL-6 and CRP [96]. Muscle fibre cross-sectional area (CSA) hypertrophy and improvements in muscular strength were inversely associated with changes in circulating IL-6. This is in agreement with resistance training in HD patients [85]. Whether the associations between reductions in inflammation and improved muscle anabolism are causal is unknown; nevertheless, reductions in resting IL-6 concentrations may facilitate hypertrophy. As discussed earlier, elevations in IL-6 concentrations inhibit insulin-like growth factor secretion, and inflammation is implicated in muscle catabolism [99]. On the other hand, the increased volume of metabolically active muscle may be conducive in reducing IL-6 concentrations at rest.

Table 4: Exercise intervention studies in predialysis chronic kidney disease patients.

Study
Design

(Number of patients)
Training
Outcome measures:

exercise versus control (unless stated otherwise)

Castaneda et al., 2004 [96]
RCT

(14 EX versus 12 CON)

(median GFR 27.5 ml/min/1.73 m²)
Supervised

5x resistance exercise machines

3 sets, 8 reps @ 80% 1 RM (progressive)

3x/wk, 12 wks
Type I muscle fibre CSA: 24% versus −14%

Type II muscle fibre CSA: 22% versus −13%

Muscle strength: +86 ± 45 kg versus −35 ± 62 kg

CRP: −1.7 mg/L versus +1.5 mg/L

IL-6: −4.2 pg/mL versus 2.3 pg/mL

Headley et al., 2012 [97]
RCT

(10 EX versus 11 CON)

(CKD stage 2–4)
Mixed aerobic training up to

55 min @ 50–60% VO2peak and some resistance exercises

3x/wk, 48 wks
VO2peak: 18.1 to 19.5 versus 18.8 to

17.0 mL/kg/min

hs-CRP: NC

IL-6: NC

Leehey et al., 2009 [98]
RCT

(7 EX versus 4 CON)

CKD stage 2–4
Walking exercise >30 min 3x/wk

6 wks supervised followed by

18 wks home based
Exercise duration at 0, 6, and 24 wks:

EX: 6.6 to 11.3 to 10.2 min versus CON: NC

CRP: NC

CON: control; CRP: C-reactive protein; CSA: cross-sectional area; EX: exercise; GFR: glomerular filtration rate; IL: interleukin; NC: no significant changes; RCT: randomised controlled trial; RM: repetition maximum.

Elsewhere, a couple of training studies found no alterations in IL-6 or CRP in predialysis patients [97, 98]. Despite a large duration, a programme of supervised mixed aerobic and resistance training lasting 48 weeks improved aerobic capacity but did not alter concentrations of IL-6 or CRP [97]. Unpublished work from our group found that six months of regular walking exercise in predialysis patients reduced IL-6 and increased IL-10 concentrations at rest, therefore improving the ratio of IL-6 to IL-10 toward a less inflammatory environment.

6. Weaknesses of Current Literature

Overall, the current available literature is unable to provide conclusive evidence of an anti-inflammatory adaptation to physical training in CKD patients. A number of factors may account for the inconsistent findings reported in intervention studies.

Unfortunately, much of the available research is primitive pilot or feasibility work for which circulating inflammatory factors are secondary outcome measures. Consequently, a number of studies are without a control group to make valid comparisons [89–91].

None of the present available research has an exercise group greater than 30 patients; the small cohorts are perhaps underpowered to preclude type II errors. Large inter-individual differences are seen in IL-6 and CRP in healthy populations [100]; this is exacerbated by the variability of the condition of patients with CKD, and their different comorbidities and aetiology [101]. It is unsurprising that small studies with cohorts of mixed condition have failed to find significant changes. Large-scale multicentre studies are needed with large randomised training cohorts and matched control groups.

There are no set guidelines or exercise protocols for CKD patients, and so a large variety of exercise treatments have been tested. For many patients heart rate and VO₂ are not appropriate measures of intensity due to medications and haemodialysis treatment; therefore, subjective measures such as the rating of perceived exertion (RPE) are utilised [102]. Differences in exercise modalities, duration and intensity give different training adaptations and therefore make comparisons between separate studies difficult. One study has made the comparison between different exercise modalities in ESRD patients but found no changes in CRP, TNF-α or IL-6 in groups performing aerobic exercise, resistance exercise or a combination of the two [86].

Other potential explanations for discrepancies between studies include large variability in baseline inflammatory values of study participants, different assays used, and differences in the time taken to collect post-training samples [50].

7. Discussion

Data from intervention studies in CKD patients has so far been inconclusive; nonetheless, research in other clinical populations associated with elevated chronic inflammation has shown more promising results. Significant improvements in inflammatory status after short-duration exercise programmes have been seen in patients with type 2 diabetes mellitus [103], metabolic syndrome [104], ischaemic heart disease [105], and chronic heart failure [106]. Why these populations have more frequently reported benefits from exercise than CKD patients is unclear. Wilund and colleagues suggest the anti-inflammatory effects of regular physical activity that are observed in the general population, and other chronic diseases may not be adequate to alter the severe inflammation seen in ESRD [88]. However, it has been reported elsewhere that individuals with the poorest baseline values are often the most susceptible to improvement [50, 105].

The proposed benefits of exercise on inflammation may be a result of repeated acute-bout effects rather than a sustained basal state alteration. The release of the “myokine” IL-6 from contracting muscle stimulates an anti-inflammatory cascade [107]. Basal levels of IL-6, TNF-α, and IL-10 are frequently elevated in CKD, especially in ESRD [36]; therefore regular exercise and repeated transient large-scale increases in IL-6 and anti-inflammatory factors that follow (IL-1ra, cortisol and IL-10) may have particularly important anti-inflammatory effects.

To our knowledge no studies have reported the acute effects of exercise on inflammatory markers in CKD. Unpublished results from our group found an increase in IL-6 and IL-10 concentrations immediately after and 1 hour after an acute bout of 30-minute moderate-intensity walking exercise in predialysis patients; an exercise intensity lower than normally expected to induce IL-6 secretion from muscle [58]. The exercise stimulus required to elicit acute IL-6 secretion from myocytes may in fact be lower in CKD. At rest muscle IL-6 expression is upregulated in ESRD patients displaying an inflammatory response, potentially due to inhibited muscular glucose uptake or increased reactive oxygen species and metabolic acidosis [108], suggesting that a reduced stimulus would be required to expand secretion. In addition, IL-6 release at rest was associated with a negative protein balance in ESRD but not in predialysis CKD patients. Importantly, none of the available literature indicates that exercise may increase basal levels of inflammation or muscle catabolism, signifying a differentiation between IL-6 concentrations at rest and transient elevations due to exercise. Further studies are required to determine the acute IL-6 response to exercise in CKD patients and the duration of such changes. The challenge is in developing exercise programmes which stimulate anti-inflammatory responses but are also feasible and practical in patients with reduced physical function.

Alternatively, it could be suggested that the training stimulus in the current literature is not sufficient to cause an adaptation. In a high-intensity interval training study (3-weekly sessions of 15× 1-minute intervals at 90% HRpeak) in renal transplant patients large reductions in IL-6 were reported after 10 weeks (before versus after  pg/mL) [109]. Although this study had no control group this may represent a training load required to stimulate a significant adaptation.

A reduction in adipose tissue has been proposed as a major mechanism for restricting chronic inflammation [51]. Physical activity has a key role in weight loss programmes within the CKD population; patients who regularly take part in exercise are more likely to succeed in achieving planned weight loss by inducing a greater energy deficit [110]. No studies thus far have investigated inflammatory markers in CKD patients taking part in planned weight-loss programmes. Since adipose tissue and indwelling macrophages are major contributors to circulating concentrations of pro-inflammatory adipokines leptin, resistin, TNF-α, and IL-6 amongst others [23], and truncal fat mass is associated with increased levels of inflammation in ESRD [111], it is intuitive to suggest a successful reduction in fat-mass and shift in body composition would have anti-inflammatory benefits in CKD patients; further research is required in this area.

ESRD patients have been reported to have over 3-fold elevations in pro-inflammatory monocytes (CD14lowCD16⁺) which contribute significantly to inflammation despite representing only 5.5% of monocytes in healthy subjects [112, 113]. Furthermore, TLR2 and TLR4 have been shown to be up-regulated [114], and regulatory T cell numbers and capacity are suppressed [115, 116]. Since exercise training may redress these imbalances in other populations [51], future research should investigate these mechanisms.

8. Conclusions

From the sparse data available some tentative conclusions can be drawn. Observational data suggests that habitual physical activity levels and fitness are associated with a reduced inflammatory profile and consequently improved survival.

A few, small, short-duration intervention studies which increase physical fitness, strength, and activity levels have mixed effects on systemic inflammation in CKD patients; this follows similar results from short-duration studies in the general population although training in other chronic disease cohorts has demonstrated beneficial effects. In CKD patients there are other numerous benefits of regular exercise, and importantly, it has not been shown to have any detrimental effect in terms of inducing inflammation or muscle catabolism. In fact, the greatest degrees of muscle hypertrophy are associated with the greatest improvements in markers of inflammation.

Data in healthy groups have shown improvements in inflammatory factors through reductions in fat mass, the regular release of anti-inflammatory myokines, and adaptations to leukocytes including phenotypic switching, expression of TLRs and numbers of circulating regulatory T lymphocytes. These represent future areas for research.

Development of exercise programmes in chronic kidney disease to maximise benefits for the patient provides a challenge. The CKD population are frequently sedentary and present chronic systemic inflammation; there may be great potential for long-term exercise interventions to shift habitual activity and improve health status.

References

M. Longmore, I. B. Wilkinson, E. H. Davidson, A. Foulkes, and A. R. Mafi, Oxford Handbook of Clinical Medicine, Oxford University Press, Oxford, UK, 8th edition, 2010.

National Collaborating Centre for Chronic Conditions, Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care, Royal College of Physicians, London, UK, 2008.

R. Steenkamp, C. Castledine, T. Feest, and D. Fogarty, “UK Renal Registry 13th Annual Report (December 2010): Chapter 2: UK RRT prevalence in 2009: national and centre-specific analyses,” Nephron, vol. 119, no. 2, pp. 27–52, 2011.

P. J. Kumar and M. L. Clark, Kumar and Clark's Clinical Medicine, Saunders Elsevier, Edinburgh, UK, 7th edition, 2009.

Q. L. Zhang and D. Rothenbacher, “Prevalence of chronic kidney disease in population-based studies: systematic review,” BMC Public Health, vol. 8, no. 117, 2008.

M. Tonelli, N. Wiebe, B. Culleton et al., “Chronic kidney disease and mortality risk: a systematic review,” Journal of the American Society of Nephrology, vol. 17, no. 7, pp. 2034–2047, 2006.

D. S. Keith, G. A. Nichols, C. M. Gullion, J. B. Brown, and D. H. Smith, “Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization,” Archives of Internal Medicine, vol. 164, no. 6, pp. 659–663, 2004.

N. Drey, P. Roderick, M. Mullee, and M. Rogerson, “A population-based study of the incidence and outcomes of diagnosed chronic kidney disease,” American Journal of Kidney Diseases, vol. 42, no. 4, pp. 677–684, 2003.

M. J. Sarnak, A. S. Levey, A. C. Schoolwerth et al., “Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention,” Circulation, vol. 108, no. 17, pp. 2154–2169, 2003.

E. L. Schiffrin, M. L. Lipman, and J. F. E. Mann, “Chronic kidney disease: effects on the cardiovascular system,” Circulation, vol. 116, no. 1, pp. 85–97, 2007.

P. Libby P, “Inflammation and cardiovascular disease mechanisms,” The American Journal of Clinical Nutrition, vol. 83, no. 2, pp. 456–460, 2006.

N. Khansari, Y. Shakiba, and M. Mahmoudi, “Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer,” Recent Patents on Inflammation and Allergy Drug Discovery, vol. 3, no. 1, pp. 73–80, 2009.

A. X. Garg, P. G. Blake, W. F. Clark, C. M. Clase, R. B. Haynes, and L. M. Moist, “Association between renal insufficiency and malnutrition in older adults: results from the NHANES III,” Kidney International, vol. 60, no. 5, pp. 1867–1874, 2001.

O. Ortega, I. Rodriguez, P. Gallar et al., “Significance of high C-reactive protein levels in pre-dialysis patients,” Nephrology Dialysis Transplantation, vol. 17, no. 6, pp. 1105–1109, 2002.

B. P. Oberg, E. McMenamin, F. L. Lucas et al., “Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease,” Kidney International, vol. 65, no. 3, pp. 1009–1016, 2004.

P. Zaoui and R. M. Hakim, “The effects of the dialysis membrane on cytokine release,” Journal of the American Society of Nephrology, vol. 4, no. 9, pp. 1711–1718, 1994.

W. E. M. Schouten, M. P. C. Grooteman, A. J. van Houte, M. Schoorl, J. van Limbeek, and M. J. Nubé, “Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis,” Nephrology Dialysis Transplantation, vol. 15, no. 3, pp. 379–384, 2000.

G. A. Kaysen, “Inflammation nutritional state and outcome in end stage renal disease,” Mineral and Electrolyte Metabolism, vol. 25, no. 4–6, pp. 242–250, 1999.

M. Arici and J. Walls, “End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?” Kidney International, vol. 59, no. 2, pp. 407–414, 2001.

C. L. Meuwese, S. Snaedal, N. Halbesma et al., “Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarly associated with survival in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 26, no. 4, pp. 1313–1318, 2011.

G. Tripepi, F. Mallamaci, and C. Zoccali, “Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. S83–S88, 2005.

D. V. Barreto, F. C. Barreto, S. Liabeuf et al., “Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease,” Kidney International, vol. 77, no. 6, pp. 550–556, 2010.

N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 85–97, 2011.

N. D. Vaziri, M. V. Pahl, A. Crum, and K. Norris, “Effect of uremia on structure and function of immune system,” Journal of Renal Nutrition, vol. 22, no. 1, pp. 149–156, 2012.

A. Steensberg, C. P. Fischer, C. Keller, K. Møller, and B. K. Pedersen, “IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans,” American Journal of Physiology—Endocrinology and Metabolism, vol. 285, no. 2, pp. E433–E437, 2003.

W. W. Cheung, K. H. Paik, and R. H. Mak, “Inflammation and cachexia in chronic kidney disease,” Pediatric Nephrology, vol. 25, no. 4, pp. 711–724, 2010.

J. J. Carrero and P. Stenvinkel, “Inflammation in end-stage renal disease-what have we learned in 10 years?” Seminars in Dialysis, vol. 23, no. 5, pp. 498–509, 2010.

K. Kalantar-Zadeh, “Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: what is next?” Seminars in Dialysis, vol. 18, no. 5, pp. 365–369, 2005.

P. W. F. Wilson, R. B. D’Agostino, D. Levy, A. M. Belanger, H. Silbershatz, and W. B. Kannel, “Prediction of coronary heart disease using risk factor categories,” Circulation, vol. 97, no. 18, pp. 1837–1847, 1998.

K. Kalantar-Zadeh, T. A. Ikizler, G. Block, M. M. Avram, and J. D. Kopple, “Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences,” American Journal of Kidney Diseases, vol. 42, no. 5, pp. 864–881, 2003.

G. Strassmann, M. Fong, J. S. Kenney, and C. O. Jacob, “Evidence for the involvement of interleukin 6 in experimental cancer cachexia,” Journal of Clinical Investigation, vol. 89, no. 5, pp. 1681–1684, 1992.

R. Pecoits‐Filho, P. Bárány, B. Lindholm, O. Heimbürger, and P. Stenvinkel, “Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment,” Nephrology Dialysis Transplantation, vol. 17, no. 9, pp. 1684–1688, 2002.

M. Barbieri, L. Ferrucci, E. Ragno et al., “Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons,” American Journal of Physiology—Endocrinology and Metabolism, vol. 284, no. 3, pp. E481–E487, 2003.

D. Mafra, A. Jolivot, P. Chauveau et al., “Are ghrelin and leptin involved in food intake and body mass index in maintenance hemodialysis?” Journal of Renal Nutrition, vol. 20, no. 3, pp. 151–157, 2010.

W. Cheung, P. X. Yu, B. M. Little, R. D. Cone, D. L. Marks, and R. H. Mak, “Role of leptin and melanocortin signaling in uremia-associated cachexia,” Journal of Clinical Investigation, vol. 115, no. 6, pp. 1659–1665, 2005.

P. Stenvinkel, M. Ketteler, R. J. Johnson et al., “IL-10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly,” Kidney International, vol. 67, no. 4, pp. 1216–1233, 2005.

M. Girndt, H. Kohler, E. Schiedhelm-Weick, J. F. Schlaak, K. H. Meyer Zum Buschenfelde, and B. Fleischer, “Production of interleukin-6, tumor necrosis factor α and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients,” Kidney International, vol. 47, no. 2, pp. 559–565, 1995.

K. Kalantar-Zadeh, G. Block, C. J. McAllister, M. H. Humphreys, and J. D. Kopple, “Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients,” The American Journal of Clinical Nutrition, vol. 80, no. 2, pp. 299–307, 2004.

American College of Sports Medicine, “Exercise is Medicine,” 2012, http://exerciseismedicine.org/physicians.htm

C. Kasapis and P. D. Thompson, “The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review,” Journal of the American College of Cardiology, vol. 45, no. 10, pp. 1563–1569, 2005.

E. A. Bermudez, N. Rifai, J. Buring, J. E. Manson, and P. M. Ridker, “Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 10, pp. 1668–1673, 2002.

T. S. Church, C. E. Barlow, C. P. Earnest, J. B. Kampert, E. L. Priest, and S. N. Blair, “Associations between cardiorespiratory fitness and C-reactive protein in men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 11, pp. 1869–1876, 2002.

L. H. Colbert, M. Visser, E. M. Simonsick, et al., “Physical activity, exercise, and inflammatory markers in older adults: findings from the health, aging and body composition study,” Journal of the American Geriatrics Society, vol. 52, no. 7, pp. 1098–1104, 2004.

R. Elosua, B. Bartali, J. M. Ordovas, A. M. Corsi, F. Lauretani, and L. Ferrucci, “Association between physical activity, physical performance, and inflammatory biomarkers in an elderly population: the InCHIANTI study,” Journals of Gerontology. A. Biological Sciences and Medical Sciences, vol. 60, no. 6, pp. 760–767, 2005.

R. A. Shanely, D. C. Nieman, D. A. Henson, F. Jin, A. M. Knab, and W. Sha, “Inflammation and oxidative stress are lower in physically fit and active adults,” Scandinavian Journal of Medicine and Science in Sports, vol. 23, no. 2, pp. 215–223, 2011.

M. Hamer, S. Sabia, G. D. Batty et al., “Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study,” Circulation, vol. 126, no. 8, pp. 928–933, 2012.

T. Christiansen, S. K. Paulsen, J. M. Bruun, S. B. Pedersen, and B. Richelsen, “Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: a 12-week randomized intervention study,” American Journal of Physiology—Endocrinology and Metabolism, vol. 298, no. 4, pp. E824–E831, 2010.

T. S. Church, C. P. Earnest, A. M. Thompson et al., “Exercise without weight loss does not reduce C-reactive protein: the INFLAME study,” Medicine and Science in Sports and Exercise, vol. 42, no. 4, pp. 708–716, 2010.

L. K. Stewart, C. P. Earnest, S. N. Blair, and T. S. Church, “Effects of different doses of physical activity on C-reactive protein among women,” Medicine and Science in Sports and Exercise, vol. 42, no. 4, pp. 701–707, 2010.

D. Thompson, D. Markovitch, J. A. Betts, D. Mazzatti, J. Turner, and R. M. Tyrrell, “Time course of changes in inflammatory markers during a 6-mo exercise intervention in sedentary middle-aged men: a randomized-controlled trial,” Journal of Applied Physiology, vol. 108, no. 4, pp. 769–779, 2010.

M. Gleeson, N. C. Bishop, D. J. Stensel, M. R. Lindley, S. S. Mastana, and M. A. Nimmo, “The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease,” Nature Reviews Immunology, vol. 11, no. 9, pp. 607–615, 2011.

M. Uguccioni, M. D'Apuzzo, M. Loetscher, B. Dewald, and M. Baggiolini, “Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1α and MIP-1β on human monocytes,” European Journal of Immunology, vol. 25, no. 1, pp. 64–68, 1995.

U. Kintscher, M. Hartge, K. Hess et al., “T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 7, pp. 1304–1310, 2008.

M. Keophiphath, C. Rouault, A. Divoux, K. Clément, and D. Lacasa, “CCL5 promotes macrophage recruitment and survival in human adipose tissue,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 1, pp. 39–45, 2010.

J. L. Abramson and V. Vaccarino, “Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults,” Archives of Internal Medicine, vol. 162, no. 11, pp. 1286–1292, 2002.

B. K. Pedersen and M. A. Febbraio, “Muscle as an endocrine organ: focus on muscle-derived interleukin-6,” Physiological Reviews, vol. 88, no. 4, pp. 1379–1406, 2008.

K. Ostrowski, T. Rohde, S. Asp, P. Schjerling, and B. K. Pedersen, “Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans,” Journal of Physiology, vol. 515, part 1, pp. 287–291, 1999.

C. P. Fischer, “Interleukin-6 in acute exercise and training: what is the biological relevance?” Exercise Immunology Review, vol. 12, pp. 6–33, 2006.

J. M. Peake, K. Nosaka, M. Muthalib, and K. Suzuki, “Systemic inflammatory responses to maximal versus submaximal lengthening contractions of the elbow flexors,” Exercise Immunology Review, vol. 12, pp. 72–85, 2006.

M. D. Phillips, J. B. Mitchell, L. M. Currie-Elolf, R. C. Yellott, and K. A. Hubing, “Influence of commonly employed resistance exercise protocols on circulating IL-6 and indices of insulin sensitivity,” Journal of Strength and Conditioning Research, vol. 24, no. 4, pp. 1091–1101, 2010.

C. Keller, A. Steensberg, A. K. Hansen, C. P. Fischer, P. Plomgaard, and B. K. Pedersen, “Effect of exercise, training, and glycogen availability on IL-6 receptor expression in human skeletal muscle,” Journal of Applied Physiology, vol. 99, no. 6, pp. 2075–2079, 2005.

B. K. Pedersen and C. P. Fischer, “Beneficial health effects of exercise–the role of IL-6 as a myokine,” Trends in Pharmacological Sciences, vol. 28, no. 4, pp. 152–156, 2007.

M. G. Flynn and B. K. McFarlin, “Toll-like receptor 4: link to the anti-inflammatory effects of exercise?” Exercise and Sport Sciences Reviews, vol. 34, no. 4, pp. 176–181, 2006.

M. Gleeson, B. McFarlin, and M. Flynn, “Exercise and Toll-like receptors,” Exercise Immunology Review, vol. 12, pp. 34–53, 2006.

B. Stengel, M. E. Tarver-Carr, N. R. Powe, M. S. Eberhardt, and F. L. Brancati, “Lifestyle factors, obesity and the risk of chronic kidney disease,” Epidemiology, vol. 14, no. 4, pp. 479–487, 2003.

N. Bharakhada, T. Yates, M. J. Davies, et al., “Association of sitting time and physical activity with CKD: a cross-sectional study in family practices,” American Journal of Kidney Diseases, vol. 60, no. 4, pp. 583–590, 2012.

A. M. O'Hare, K. Tawney, P. Bacchetti, and K. L. Johansen, “Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2,” American Journal of Kidney Diseases, vol. 41, no. 2, pp. 447–454, 2003.

A. G. Stack, D. A. Molony, T. Rives, J. Tyson, and B. V. R. Murthy, “Association of physical activity with mortality in the US dialysis population,” American Journal of Kidney Diseases, vol. 45, no. 4, pp. 690–701, 2005.

A. Akber, A. A. Portale, and K. L. Johansen, “Pedometer-assessed physical activity in children and young adults with CKD,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 720–726, 2012.

K. L. Johansen and P. Painter, “Exercise in individuals with CKD,” American Journal of Kidney Diseases, vol. 59, no. 1, pp. 126–134, 2011.

E. Brodin, S. Ljungman, and K. S. Sunnerhagen, “Rising from a chair: a simple screening test for physical function in predialysis patients,” Scandinavian Journal of Urology and Nephrology, vol. 42, no. 3, pp. 293–300, 2008.

J. Padilla, J. Krasnoff, M. Da Silva et al., “Physical functioning in patients with chronic kidney disease,” Journal of Nephrology, vol. 21, no. 4, pp. 550–559, 2008.

R. G. Fassett, I. K. Robertson, D. P. Geraghty, M. J. Ball, N. W. Burton, and J. S. Coombes, “Physical activity levels in patients with chronic kidney disease entering the LORD trial,” Medicine and Science in Sports and Exercise, vol. 41, no. 5, pp. 985–991, 2009.

N. Clyne, T. Jogestrand, L. E. Lins, and S. K. Pehrsson, “Progressive decline in renal function induces a gradual decrease in total hemoglobin and exercise capacity,” Nephron, vol. 67, no. 3, pp. 322–326, 1994.

E. Segura-Orti, P. L. Gordon, J. W. Doyle, et al., “Physical functioning in chronic kidney disease: contribution of uremia,” Journal of the American Society of Nephrology, vol. 21, pp. 669A–670A, 2010.

F. Baria, M. A. Kamimura, C. M. Avesani et al., “Activity-related energy expenditure of patients undergoing hemodialysis,” Journal of Renal Nutrition, vol. 21, no. 3, pp. 226–234, 2011.

P. L. Gordon, J. W. Doyle, and K. L. Johansen, “Postdialysis fatigue is associated with sedentary behavior,” Clinical Nephrology, vol. 75, no. 5, pp. 426–433, 2011.

S. Anand, G. M. Chertow, K. L. Johansen et al., “Association of self-reported physical activity with laboratory markers of nutrition and inflammation: the Comprehensive Dialysis Study,” Journal of Renal Nutrition, vol. 21, no. 6, pp. 429–437, 2011.

D. Mafra, P. Deleaval, D. Teta et al., “Influence of inflammation on total energy expenditure in hemodialysis patients,” Journal of Renal Nutrition, vol. 21, no. 5, pp. 387–393, 2011.

S. Zamojska, M. Szklarek, M. Niewodniczy, and M. Nowicki, “Correlates of habitual physical activity in chronic haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 21, no. 5, pp. 1323–1327, 2006.

F. G. Shiraishi, F. Stringuetta Belik, O. e Silva, et al., “Inflammation, diabetes, and chronic kidney disease: role of aerobic capacity,” Experimental Diabetes Research, vol. 2012, Article ID 750286, 6 pages, 2012.

G. C. Kosmadakis, A. Bevington, A. C. Smith et al., “Physical exercise in patients with severe kidney disease,” Nephron—Clinical Practice, vol. 115, no. 1, pp. c7–c15, 2010.

S. Heiwe and S. H. Jacobson, “Exercise training for adults with chronic kidney disease,” Cochrane Database of Systematic Reviews, no. 10, Article ID CD003236, 2011.

M. Daniilidis, E. Kouidi, A. Fleva, et al., “The immune response in hemodialysis patients following physical training,” Journal of Sport Sciences for Health, vol. 1, no. 1, pp. 11–16, 2004.

B. S. B. Cheema, H. Abas, B. C. Smith, et al., “Effect of resistance training during hemodialysis on circulating cytokines: a randomized controlled trial,” European Journal of Applied Physiology, vol. 111, no. 7, pp. 1437–1445, 2011.

J. D. Kopple, H. Wang, R. Casaburi et al., “Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle,” Journal of the American Society of Nephrology, vol. 18, no. 11, pp. 2975–2986, 2007.

N. D. Toussaint, K. R. Polkinghorne, and P. G. Kerr, “Impact of intradialytic exercise on arterial compliance and B-type natriuretic peptide levels in hemodialysis patients,” Hemodialysis International, vol. 12, no. 2, pp. 254–263, 2008.

K. R. Wilund, E. J. Tomayko, P. T. Wu et al., “Intradialytic exercise training reduces oxidative stress and epicardial fat: a pilot study,” Nephrology Dialysis Transplantation, vol. 25, no. 8, pp. 2695–2701, 2010.

T. Gołębiowski, M. Kusztal, W. Weyde, et al., “A program of physical rehabilitation during hemodialysis sessions improves the fitness of dialysis patients,” Kidney and Blood Pressure Research, vol. 35, no. 4, pp. 290–296, 2012.

A. Załuska, W. T. Załuska, A. Bednarek-Skublewska, and A. Ksiazek, “Nutrition and hydration status improve with exercise training using stationary cycling during hemodialysis (HD) in patients with end-stage renal disease (ESRD),” Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina, vol. 57, no. 2, pp. 342–346, 2002.

B. C. Nindl, S. A. Headley, A. P. Tuckow et al., “IGF-I system responses during 12 weeks of resistance training in end-stage renal disease patients,” Growth Hormone & IGF Research, vol. 14, no. 3, pp. 245–250, 2004.

B. Cheema, H. Abas, B. Smith et al., “Progressive exercise for anabolism in kidney disease (PEAK): a randomized, controlled trial of resistance training during hemodialysis,” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1594–1601, 2007.

R. Afshar, L. Shegarfy, N. Shavandi, and S. Sanavi, “Effects of aerobic exercise and resistance training on lipid profiles and inflammation status in patients on maintenance hemodialysis,” Indian Journal of Nephrology, vol. 20, no. 4, pp. 185–189, 2010.

R. Afshar, A. Emany, A. Saremi, N. Shavandi, and S. Sanavi, “Effects of intradialytic aerobic training on sleep quality in hemodialysis patients,” Iranian Journal of Kidney Diseases, vol. 5, no. 2, pp. 119–123, 2011.

S. Headley, M. Germain, P. Mailloux et al., “Resistance training improves strength and functional measures in patients with end-stage renal disease,” American Journal of Kidney Diseases, vol. 40, no. 2, pp. 355–364, 2002.

C. Castaneda, P. L. Gordon, R. C. Parker, K. L. Uhlin, R. Roubenoff, and A. S. Levey, “Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease,” American Journal of Kidney Diseases, vol. 43, no. 4, pp. 607–616, 2004.

S. Headley, M. Germain, C. Milch, et al., “Exercise Training Improves HR responses and VO2peak in Predialysis Kidney Patients,” Medicine and Science in Sports and Exercise, vol. 44, no. 12, pp. 2392–2399, 2012.

D. J. Leehey, I. Moinuddin, J. P. Bast et al., “Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study,” Cardiovascular Diabetology, vol. 8, article 62, 2009.

F. Haddad, F. Zaldivar, D. M. Cooper, and G. R. Adams, “IL-6-induced skeletal muscle atrophy,” Journal of Applied Physiology, vol. 98, no. 3, pp. 911–917, 2005.

E. M. Macy, T. E. Hayes, and R. P. Tracy, “Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications,” Clinical Chemistry, vol. 43, no. 1, pp. 52–58, 1997.

J. A. Eustace, B. Astor, P. M. Muntner, T. A. Ikizler, and J. Coresh, “Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease,” Kidney International, vol. 65, no. 3, pp. 1031–1040, 2004.

G. A. V. Borg, “Perceived exertion: a note on “ history” and methods,” Medicine and Science in Sports and Exercise, vol. 5, no. 2, pp. 90–93, 1973.

N. P. E. Kadoglou, F. Iliadis, N. Angelopoulou et al., “The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 14, no. 6, pp. 837–843, 2007.

M. Trøseid, K. T. Lappegrd, T. E. Mollnes, H. Arnesen, and I. Seljeflot, “The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome,” Metabolic Syndrome and Related Disorders, vol. 7, no. 6, pp. 579–583, 2009.

E. Goldhammer, A. Tanchilevitch, I. Maor, Y. Beniamini, U. Rosenschein, and M. Sagiv, “Exercise training modulates cytokines activity in coronary heart disease patients,” International Journal of Cardiology, vol. 100, no. 1, pp. 93–99, 2005.

A. I. Larsen, P. Aukrust, T. Aarsland, and K. Dickstein, “Effect of aerobic exercise training on plasma levels of tumor necrosis factor alpha in patients with heart failure,” American Journal of Cardiology, vol. 88, no. 7, pp. 805–808, 2001.

A. M. W. Petersen and B. K. Pedersen, “The anti-inflammatory effect of exercise,” Journal of Applied Physiology, vol. 98, no. 4, pp. 1154–1162, 2005.

G. Garibotto, A. Sofia, V. Procopio et al., “Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: effects of end-stage renal disease and microinflammatory state,” Kidney International, vol. 70, no. 2, pp. 384–390, 2006.

G. Romano, R. Simonella, E. Falleti et al., “Physical training effects in renal transplant recipients,” Clinical Transplantation, vol. 24, no. 4, pp. 510–514, 2010.

H. L. MacLaughlin, P. A. Sarafidis, S. A. Greenwood, K. L. Campbell, W. L. Hall, and I. C. Macdougall, “Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease,” American Journal of Hypertension, vol. 25, no. 9, pp. 1024–1029, 2012.

J. Axelsson, A. R. Qureshi, M. E. Suliman et al., “Truncal fat mass as a contributor to inflammation in end-stage renal disease,” The American Journal of Clinical Nutrition, vol. 80, no. 5, pp. 1222–1229, 2004.

A. Merino, P. Buendia, A. Martin-Malo, P. Aljama, R. Ramirez, and J. Carracedo, “Senescent CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity,” Journal of Immunology, vol. 186, no. 3, pp. 1809–1815, 2011.

K. U. Belge, F. Dayyani, A. Horelt et al., “The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF,” Journal of Immunology, vol. 168, no. 7, pp. 3536–3542, 2002.

P. Gollapudi, J. W. Yoon, S. Gollapudi, M. V. Pahl, and N. D. Vaziri, “Leukocyte toll-like receptor expression in end-stage kidney disease,” American Journal of Nephrology, vol. 31, no. 3, pp. 247–254, 2010.

T. K. Hendrikx, E. A. F. J. van Gurp, W. M. Mol et al., “End-stage renal failure and regulatory activities of CD4 +CD25bright+FoxP3+ T-cells,” Nephrology Dialysis Transplantation, vol. 24, no. 6, pp. 1969–1978, 2009.

P. Meier, D. Golshayan, E. Blanc, M. Pascual, and M. Burnier, “Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD,” Journal of the American Society of Nephrology, vol. 20, no. 6, pp. 1368–1384, 2009.